Exelixis, Inc.
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients…
Biotechnology
US, Alameda [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
1
Financial Health
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Current Ratio | 3.65 | 3.46 | 3.34 | |
| Debt/Assets | n.A. | n.A. | n.A. | |
| Debt/Equity | n.A. | n.A. | n.A. | |
| Net Debt/EBITDA | 30.81 | -0.57 | -0.83 | |
| Naive Interpretation | member | |||
2
Per Share
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Book Value | -3.59 | 7.08 | 7.34 | |
| Cash | -0.73 | 3.20 | 3.23 | |
| Capex | -42.05 | -0.06 | -0.04 | |
| Free Cash Flow | 1925.41 | 0.17 | < 0.005 | |
| Revenue | -9.07 | 1.41 | 1.55 | |
| Naive Interpretation | member | |||
3
Profitability
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Gross Margin | -0.49 | 0.95 | 0.95 | |
| Operating Margin | -59.37 | 0.07 | 0.17 | |
| ROA | -54.21 | 0.01 | 0.03 | |
| ROE | -53.58 | 0.02 | 0.04 | |
| ROIC | -64.95 | < 0.005 | 0.03 | |
| Naive Interpretation | member | |||
4
Valuation
The "Valuation Entry" for the Focus of EXEL is permitted for members.
5
Growth
The "Growth Entry" for the Focus of EXEL is permitted for members.
6
Leverage & Liquidity